Home> Products> Inhibitors> BV6-CAS 1001600-56-1
price inquiry for CAS:1001600-56-1, Product:BV6

BV6 CAS: 1001600-56-1

Category: Inhibitors
Product Name: BV6
Cat No: I000074
CAS No: 1001600-56-1
Synonyms: BV-6
Molecular Formula: C70H96N10O8
Molecular Weight: 1205.57
SMILES: O=C(CCCCCCCNC([C@@H](NC([C@H]1N(C([C@H](C2CCCCC2)NC([C@H](C)NC)=O)=O)CCC1)=O)CO=C(NCCCCCCNC([C@@H](NC([C@H]1N(C([C@H](C2CCCCC2)NC([C@H](C)NC)=O)=O)CCC1)=O)C(C3=CC=CC=C3)C4=CC=CC=C4)=O)[C@@H](NC([C@H]5N(C([C@H](C6CCCCC6)NC([C@H](C)NC)=O)=O)CCC5)=O)C(C7=CC=
Solubility: DMSO: ≥ 58 mg/mL
Target: IAP
Storage: Store at -20°C
CAS 1001600-56-1,BV6
  • Description

BV6 is a small-molecule Smac mimetic, which antagonizes IAP and induces autoubiquitination and subsequent proteasomal degradation of cIAP1 and cIAP2. 

in vitro: BV6 treatment had no effect on necrotic cell death induced by poly(I:C)+IFNβ, anti-Fas+zVAD-fmk, or H2O2, but greatly sensitized cells to TNF-induced necrosis. As observed in L929 cells, BV6 treatment of FADD-deficient Jurkat cells led to a rapid loss of cIAP1 and cIAP2 and greatly sensitized these cells to TNF-induced necrosis [1]. BV6 significantly enhances the radiosensitization of HCC193 and H460 cells in vitro [2]. Four-hour pre-incubation with 2.5μMol BV6 moderately enhanced CIK cell-mediated lysis of hematological (H9, THP-1, and Tanoue) and solid malignancies (RH1, RH30, and TE671). However, BV6 also increased apoptosis of non-malignant cells like peripheral blood mononuclear cells and most notably had an inhibitory effect on immune cells potentially limiting their cytotoxic potential [3].

  • References

[1]. Vanlangenakker N, et al. cIAP1 and TAK1 protect cells from TNF-induced necrosis by preventing RIP1/RIP3-dependent reactive oxygen species production. Cell Death Differ. 2011 Apr;18(4):656-65. 

[2]. Li W, et al. BV6, an IAP antagonist, activates apoptosis and enhances radiosensitization of non-small cell lung carcinoma in vitro. J Thorac Oncol. 2011 Nov;6(11):1801-9. 

[3]. Rettinger E, et al. SMAC Mimetic BV6 Enables Sensitization of Resistant Tumor Cells but also Affects Cytokine-Induced Killer (CIK) Cells: A Potential Challenge for Combination Therapy. Front Pediatr. 2014 Jul 18;2:75.


price inquiry for CAS:1001600-56-1, Product:BV6